Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2024 · 10-Q
Revenue$12.30M$12.30M+33.6% vs Q3 2023 Net Income$1.68M$1.68MN/M vs Q3 2023 EPS Diluted$0.38$0.38N/M vs Q3 2023 Gross Profit$7,902,000+46.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,116,000+91.5% Free Cash Flowderived$1,594,000+67.3% Margins · derivedGross margin64.3%+5.8 pt vs Q3 2023
Operating margin18.7%+14.2 pt vs Q3 2023
Net margin13.6%+15.7 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 8, 2024 · 39 d after period end